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ABSTRACT 
The Frequency and Impact of Fibroblast Growth Factor Receptor 1 
Amplification and p16 Protein Expression on Clinical Outcomes  
in Resected Head and Neck Squamous Cell Carcinoma 
 
Su Jin Heo 
 
Department of Medicine, 
 The Graduate School, Yonsei University  
 
(Directed by Professor Byoung Chul Cho) 
 
 
 
The aim of this study was to investigate the frequency and the impact of 
Fibroblast growth factor receptor1 (FGFR1) amplification and p16 protein 
expression on clinical outcomes in curatively resected head and neck squamous 
cell carcinoma (HNSCC). Tumor tissue from 383 patients with HNSCC from 
November 2005 and December 2012 were collected and analyzed using an 
FGFR1 fluorescent in situ hybridization (FISH) assay. High amplification was 
defined as percentage of tumor cells containing ≥ 9 signals in ≥ 20% cells, and 
low amplification was defined as percentage of tumor cells containing 2~8 
signals in ≥ 20% cells. High and low amplifications were detected in 1.0% and 
41.3%, respectively. In our study, the prognostic impact of FGFR1 amplification 
was not observed, probably due to tumor heterogeneity in HNSCC, 
unstandardized FISH criteria for FGFR1 amplification, varying adjuvant 
treatment, and wide variation in FGFR1 amplification group may contribute to 
the controversial result. And, as known, p16 protein expression was confirmed as 
a strong and independent predictor of survival. Further studies are needed to 
identify the criteria for FGFR1 amplification and its therapeutic efficacy. 
 
---------------------------------------------------------------------------------------- 
Key words : FGFR1, p16, squamous cell carcinoma, head and neck  
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I. INTRODUCTION 
 Head and neck squamous cell carcinoma (HNSCC) arises from mucosa lining the 
paranasal sinuses, nasal cavities, oral cavity, oropharynx, hypopharynx, and larynx. 
It is the sixth leading cancer by incidence worldwide which affect 600,000 patients 
per year with 40-50% 5-year survival rate
1
. Risk factors included tobacco use, 
alcohol consumption, human papilloma virus (HPV) infection, and genetic 
disorders such as Fanconi Anemia
1-3
. Most of patients with HNSCC are treated 
with largely uniform approach based on stage and anatomic location, typically 
using surgery, radiation therapy, and chemotherapy alone or in combination. 
Despite these multidisciplinary treatments, approximately half of all patients will 
die of the disease because of local aggressiveness and high rate of early relapse
4
. 
Cetuximab, anti-epidermal growth factor receptor (EGFR) antibody, is the only 
approved target agent in treatment of HNSCC since 2006 and yielded modest 
increases in response rate of 10-13% when used in combination with standard 
chemotherapy and radiation therapy. Unlike other types of cancers, there have 
been no validated predictive biomarkers for benefit from cetuximab in HNSCC
5
.   
Recently, the cancer genome atlas (TCGA) profiled 279 HNSCC to provide a 
comprehensive landscape of somatic genomic alterations according to HPV status, 
smoking, and primary tumor sites
6
. Nevertheless, there are no effective targeted 
3 
therapies available for HNSCC. The effort to identify the novel therapeutic targets 
and prognostic markers in HNSCC is under way.  
The Fibroblast Growth Factor Receptor (FGFR) tyrosine kinase family comprises 
four kinases: FGFR1, FGFR2, FGFR3, and FGFR4. These kinases play crucial 
roles in cancer development and targets for dysregulation by amplification, point 
mutations, and translocation in many cancers
7
. Amplification or activation of 
FGFR1 has been reported in breast adenocarcinoma, lung squamous cell cancer 
(lung SqCC), esophageal squamous cell carcinomas, ovarian cancer, bladder 
cancer, rhabdomyosarcoma, and oral squamous carcinoma
8-11
. Kim et al
12
 recently 
reported FGFR1 amplification in 13% of lung SqCC and its negative prognostic 
impact. Also, their study showed a positive association between FGFR1 
amplification and smoking dosage. In resected esophageal squamous cell 
carcinoma, high FGFR1 amplification had a greater risk of recurrence and death. 
Like in lung SqCC, high amplification was significantly higher in current smokers 
than former and never-smokers and increased proportional to smoking dosage
13
.   
Based on the histomorphological and clinical similarities between HNSCC and 
other squamous cell carcinoma, many studies have been described a potential role 
of FGFR1. In the first study about FGFR1 amplification in HNSCC, Freier et al
11
 
reported FGFR1 amplifications in 17% oral squamous cell carcinomas in a limited 
number of patient samples. Recently, Goke et al
14
 described FGFR1 amplification 
in 15% of patients with HNSCC. It was associated with nicotine and alcohol 
consumption and parameters of worse outcome, so it represents a potential role of 
therapeutic biomarker. In vivo studies have demonstrated inhibition of the FGFR1 
pathway with FGFR inhibitors that led to significant tumor shrinkage, suggesting 
that FGFR inhibitors might be and effective therapeutic option in HNSCC with 
FGFR1 amplification
15
.  
HPV status in tumors can be determined by several assays, including HPV DNA 
detection by in situ hybridization (ISH) or polymerase chain reaction (PCR), 
HPVE6/E7 RNA expression detected by quantitative reverse transcriptase–PCR 
(qRT-PCR), and/or p16 protein expression by immunohistochemistry (IHC) 
staining as a surrogate marker of oncogenic HPV infection
16-20
. Among these 
4 
assays, detection of HPV E6/E7 RNA expression, which indicates active viral 
oncogene transcription in tumor cells, is considered to be a gold standard
18,19
. 
However, because RNA isolation for qRT-PCR requires additional sample 
preparation steps and a larger amount of tumor cells compared with other assays, 
the most widely used assays are HPV ISH and p16 IHC. The p16 protein is an 
important tumor suppressor and cell-cycle regulator
21
. In HPV-positive tumors, the 
viral protein E7 binds to retinoblastoma susceptibility protein (Rb) through cullin 
2 ubiquitin ligase complex and rapidly degrades Rb by ubiquitination
22
. Loss of 
Rb results in upregulation of p16 protein expression by a feedback interaction
23,24
. 
It is well established that patients with HPV-positive/p16-positive HNSCC have a 
more favorable prognosis compared with those with HPV-negative/p16-negative 
HNSCC
16,17,20,25,26
. 
In this study, we sought to determine the frequency and the impact of FGFR1 
amplification and p16 protein expression on clinical outcomes in curatively 
resected with surgically resected HNSCC. 
 
 
II. MATERIALS AND METHODS 
1. Patients 
This study was conducted in a cohort of patients with HNSCC who 
underwent curative resection at Severance Hospital, Seoul, Korea, 
between November 2005 and December 2012. The criteria used for 
patient selection included (1) surgically resected HNSCC for curative 
aim, (2) availability of tumor tissue and clinical data on smoking status 
and survival, (3) no preoperative treatment, and (4) no distant metastasis. 
The primary tumor sites categorized in four groups as following: oral 
cavity, oropharynx, hypopharynx, and larynx. Oral cavity included hard 
palate, tongue, and buccal mucosa. Oropharynx included flour of mouth, 
base of tongue, and tonsils. Hypopharynx included pyriform sinus and 
larynx included supraglottis and glottis. We excluded 121 cases which 
had undergone the process of decalcification and 13 cases which were 
5 
not profit to produce tissue microarray. Finally, the tumor samples of 384 
patients were available for examination of FGFR1 amplification. Two 
pathologists (S.O.Y. and E.K.K.) confirmed the diagnosis of HNSCC by 
hematoxylin and eosin staining. Paraffin-embedded tumor specimens 
were used to construct a tissue microarray with 2-mm-diameter cores. 
Each patient was represented by three tissue cores. Patients’ information 
was collected by reviewing the medical records for evaluation of 
clinicopathologic characteristics and survival outcomes. Staging was 
determined using the 7
th
 edition American Joint Committee on Cancer 
(AJCC) guideline for tumor, node, and metastasis (TNM) classification. 
Never-smokers were defined as those with a lifetime smoking dose of 
fewer than 100 cigarettes, former smokers were those who had stopped 
smoking for more than 1 year, and current smokers were those who 
currently smoke or quit smoking for less than 1 year
27
.  
 
2. FGFR1 FISH method 
Fluorescent in situ hybridization (FISH) assay was performed on the 
tissue microarrays by using FGFR1 probes that hybridized to the 
8p12–8p11.23 region using the fluorophore, Spectrum Orange (red) and to 
the centromere region of chromo-some 8 (CEP 8) using the fluorophore, 
Spectrum Green (Abbott Molecular, Abbott Park, IL) following the 
manufacturers’ instructions. FISH analyses were interpreted by two 
experienced evaluators (S.O.Y. and E.K.K.) blinded to the clinical data. 
Cells with sharp borders of nuclei, no signs of overdigestion, 
non-overlapping nuclei were evaluated. Normal tissue including vessels, 
fibroblasts, or non-tumor squamous epithelium served as internal positive 
control. Cases were only further evaluated if control tissue nuclei 
displayed one or two clearly distinct signals of each color. Tumor tissue 
was scanned for amplification hot spots by using x 40 or x 63 objectives. 
If the FGFR1 signals were homogeneously distributed, then random areas 
were used for counting the signals. Twenty contiguous tumor cell nuclei 
6 
from three hot spots or random areas, resulting in a total of 60 nuclei, were 
individually evaluated with the x 100 objectives by counting red FGFR1 
and green centromere of chromosome 8 (CEP8) signals. FGFR1 
amplification was defined based on the previous study
14
 (Table1).  
 
Table1. Definition of FGFR1 amplification
14
 
High amplification Nine or more red target signals or clusters of target gene 
signals as compared with the green reference signals 
displayed in at least 20% nuclei 
Low amplification Lower than nine but more than two red target signals as 
compared with the green reference signals displayed in at 
least 20% nuclei 
 
3. p16 Immunohistochemistry 
Tumor p16 expression was evaluated by IHC using a mouse 
monocoloncal antibody (Clone E0037, Ventana, AZ, USA) and was 
visualized with the Ventana XT autostainer using the the 1-view 
secondary detection kit (Ventatn, Tuscon, AZ) for details see 
manufacturer’s recommendations. Tumor p16 expression was scored as 
positive if strong and diffuse nuclear and cytoplasmic staining was 
present in at least 75% of the tumor cells, and alternatively >50% staining 
combined with >25% confluent areas
28,29
. 
 
4. Statistical Analyses 
Our primary objective was to evaluate the frequency of FGFR1 
amplification and p16 protein expression in patients with HNSCC. Our 
secondary objectives were to identify the clinical features of patients 
with FGFR1 amplified and p16 expressed tumors and to analyze its 
impact of FGFR1 on disease-free survival (DFS) and overall survival 
(OS) in patients. DFS was measured from the time of surgery to initial 
tumor relapse (local recurrence or distant) or death as a result of any 
cause. OS, calculated from the time of surgery to death or last follow-up 
date, and 95% confidence intervals (CIs) were evaluated by survival 
7 
analysis using the Kaplan-Meier method. We used Chi-square, Fisher’s 
exact, and Mann-Whitney tests to compare the clinical factors among the 
patients with level of FGFR1 amplification and p16 status. Statistical 
significance was set at P < .05 for all analyses. Survival outcomes among 
the group were compared by using the log-rank test. Multivariate 
analysis was performed by using Cox regression analysis with the 
following prespecified variables: sex, smoking, primary tumor site, 
histologic differentiation, lymphovascular invasion, perineural invasion, 
resection margin, p16 status, pathologic T stage, pathologic N stage, and 
FGFR1 amplification according to both categories. All statistical 
analyses were performed by using SPSS version 20.0 (SPSS, Chicago, 
IL). 
 
 
III. RESULTS 
1. Patient Characteristics 
A total of 383 patients with surgically resected HNSCC were analyzed 
of FGFR1 amplification. The clinical characteristics of the enrolled 
patients are shown in Table2 and 3, divided by categories A and B. There 
were 287 (74.9%) male and 96 (25.1%) female with a median age of 58 
years (range 22-88). The majority of patients were current (40.5%) or 
former (20.4%) smokers, and median smoking dosage was 17.0 
pack-years (range 0-100). Sites of primary tumor were distributed as 
follows: 51.7% in oral cavity, 31.1% in oropharynx, 7.3% in 
hypopharynx, and 9.9% in larynx. The histologic differentiations of 
squamous cell carcinoma were 36.8% in well differentiation, 50.1% in 
moderated differentiation, and 13.1% in poor differentiation. In 
pathologic results, lymphovascular invasion was 19.1%, perineural 
invasion was 13.3%, and the positive of resection margin was 23.2%. 
About half of tumors had pathologic T1 or N0 stage. The AJCC stages 
were I in 27.9%, stage II in 11.2%, stage III in 18.0%, stage IVA in 
8 
42.3% and stage IVB in 0.5%. Adjuvant treatment was given in 242 
(63.2%) patients and of those, 95 patients were received adjuvant 
concurrent chemoradiation therapy (CCRT) and 147 patients were 
received adjuvant radiation therapy.  
 
 
Table 2. Baseline characteristics of the patients according to FGFR1 
amplification status  
Characteristics All patients 
n (%) 
High 
amplification 
n (%) 
Low 
amplification 
n (%) 
No 
amplification  
n (%) 
P-value 
Number of 
patients 
383 4 (1.0) 158 (41.3) 221 (57.7)  
Age, year     0.430 
Median 58.0 69.5 59.0 58.0  
Range 22-88 42-73 24-87 22-88  
Sex     0.631 
Male 287 (74.9) 4 (100.0) 120 (75.9) 163 (73.8)  
Female 96 (25.1) 0 (0.0) 38 (24.1) 58 (26.2)  
Smoking     0.579 
Never smoker 150 (39.2) 0 (0.0) 62 (39.2)  88 (39.8)  
Former smoker 78 (20.4) 1 (25.0) 32 (20.3) 45 (20.4)  
Current smoker 155 (40.5) 3 (75.0) 64 (40.5) 88 (39.8)  
Smoking dosage, pack/years   0.061 
Median 17.0 45.0 15.0 17.0  
Range 0-100 22-60 0-80 0-100  
Primary sites     0.206 
Oral cavity 198 (51.7) 1 (25.0) 78 (49.4) 119 (53.8)  
Oropharynx 119 (31.1) 2 (50.0) 45 (28.5) 72 (32.6)  
Hypopharynx 28 (7.3) 0 (0.0) 16 (10.1) 12 (5.4)  
Larynx 38 (9.9) 1 (25.0) 19 (12.0) 18 (8.1)  
Histologic differentiation   0.106 
  Well 
differentiated 
141 (36.8) 1 (25.0) 67 (42.4) 73 (33.0)  
  Moderated 
differentiated 
192 (50.1) 2 (50.0) 77 (48.7) 113 (51.1)  
  Poorly 
differentiated 
50 (13.1) 1 (25.0) 14 (9.9) 35 (15.8)  
Lymphovascular invasion     0.322 
Yes 73 (19.1) 1 (25.0) 35 (22.2) 37 (16.7)  
No 310 (80.9) 3 (75.0) 123 (77.8) 184 (83.3)  
9 
Perineural invasion     0.555 
Yes 51 (13.3) 1 (25.0) 20 (12.7) 30 (13.6)  
No 332 (86.7) 3 (75.0) 138 (87.3) 191 (86.4)  
Resection margin    0.310 
Positive 89 (23.2) 2 (50.0) 34 (21.5) 53 (24.0)  
Negative 294 (76.8) 2 (50.0) 124 (78.5) 168 (76.0)  
T stage     0.946 
T1 169 (44.1) 2 (50.0) 69 (43.7) 98 (44.3)  
T2 145 (37.9) 2 (50.0) 60 (38.0) 83 (37.6)  
T3 29 (7.6) 0 (0.0) 10 (6.3) 19 (8.6)  
T4 40 (10.4) 0 (0.0) 19 (12.0) 21 (9.5)  
N stage     0.986 
N0 167 (43.6) 2 (50.0) 71 (44.9) 94 (42.5)  
N1 69 (18.0) 0 (0.0) 28 (17.7) 41 (18.6)  
N2 145 (37.9) 2 (50.0) 58 (36.7) 85 (38.5)  
N3 2 (0.5) 0 (0.0) 1 (0.6) 1 (0.5)  
AJCC stage     0.870 
  Stage I 107 (27.9) 1 (25.0) 44 (27.8) 62 (28.1)  
Stage II 43 (11.2) 1 (25.0) 21 (13.3) 21 (9.5)  
  Stage III  69 (18.0) 0 (0.0) 27 (17.1) 42 (19.0)  
Stage IVA 162 (42.3) 2 (50.0) 65 (41.1) 95 (43.0)  
Stage IVB 2 (0.5) 0 (0.0) 1 (0.6) 1 (0.5)  
Adjuvant treatment    0.079 
CCRT 95 (24.8) 3 (75.0) 43 (27.2) 49 (22.2)  
Radiotherapy 147 (38.4) 0 (0.0) 47 (29.7) 100 (45.2)  
No  141 (36.8) 1 (25.0) 68 (43.0) 72 (32.6)  
FGFR1 FISH amplification      
Number 
(median, range) 
2.08 
(1.55-10.08) 
7.30 
(6.75-10.08) 
2.67 
(1.97-6.08) 
2.08 
(1.55-2.47) 
<0.001 
FGFR1/CEP8 
ratio 
(median, range) 
0.99 
(0.43-5.13) 
3.40 
(2.40-5.13) 
0.97 
(0.43-2.76) 
0.99 
(0.48-1.24) 
<0.001 
p16 status     0.043 
Positive 162 (42.3) 0 (0.0) 59 (37.3) 103 (46.6)  
Negative 221 (57.7) 4 (100.0) 99 (62.7) 118 (53.4)  
Abbreviations: AJCC, American Joint Committee on Cancer; CCRT, Concurrent 
chemoradiation therapy ; FGFR1, Fibroblast Growth Factor Receptor1; FISH, Fluorescent 
in situ hybridization 
 
2. FGFR1 Amplification and p16 status 
Among a total of 383 patients, 4 (1.0%) were high FGFR1 
amplification, 158 (41.3%) were low FGFR1 amplification, and 221 
10 
(57.7%) were no amplification (Table2; Figure1). The median FGFR1 
gene copy number per nucleus and the mean FGFR1/CEN8 ratio in all 
patients were 2.08 (range, 1.55 to 10.08 copies per nucleus) and 0.99 
(range, 0.43 to 5.13). The median FGFR1 gene copy number was 7.30 
(range, 6.75 to 10.08) in high amplification, 2.67 (range, 1.97 to 6.08) in 
low amplification, and 2.08 (range 1.55 to 2.47) in no amplification 
group. The median FGFR1/CEN8 ratio was 3.40 (range 2.40 to 5.13), 
0.97 (range, 0.43 to 2.76), and 0.99 (range, 0.48 to 1.24) in high, low and 
no amplification group, respectively. The p16 negative status related to 
unfavorable prognosis was 100% in high amplification, 62.7% in low 
amplification, and 53.4% in no amplification. There was statistically 
significant difference among these three groups. 
 
Figure 1. Fibroblast growth factor receptor1 (FGFR1) amplification   
assessed by fluorescent in situ hybridization (FISH). (A) High FGFR1   
amplification; (B) low FGFR1 amplification; (C) no amplification. 
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Based on p16 status, 162 (42.4%) patients were p16 positive and 221 
12 
(57.6%) patients were p16 negative in total cohort (Table 3). There were 
significant difference in smoking status, primary sites, histologic 
differentiation, lymphovascular invasion, resection margin, pathologic 
stage, and FGFR1 amplification between two groups. In primary tumor 
sites, oropharynx was most common in p16 positive group, and oral 
cavity, hypopharynx, larynx were relatively common in p16 negative 
group. Favorable histologic differentiation, no lymphovascular invasion, 
negative resection margin, early pathologic stage which known to related 
to good prognosis were common in p16 negative group. In contrast, gene 
copy number of FGFR1 amplification was higher in p16 negative group 
than in p16 positive group. 
 
Table 3. Baseline characteristics of the patients according to p16 status 
Characteristics All patients 
n (%) 
p16 positive 
n (%) 
p16 negative 
n (%) 
P-value 
Number of patients 383 162 (42.4) 221 (57.6)  
Age, year    0.465 
Median 58.0 57.0 59.0  
Range 22-88 23-87 22-88  
Sex    0.925 
Male 287 (74.9) 121 (74.7) 166 (75.1)  
Female 96 (25.1) 41 (25.3) 55 (24.9)  
Smoking    0.037 
Never smoker 150 (39.2) 69 (42.6) 81 (36.7)  
Former smoker 78 (20.4) 23 (14.2) 55 (24.9)  
Current smoker 155 (40.5) 70 (43.2) 85 (38.5)  
Smoking dosage, pack/years  0.979 
Median 17.0 15.0 20.0  
Range 0-100 0-100 0-100  
Primary sites    <0.001 
Oral cavity 198 (51.7) 51 (31.5) 147 (66.5)  
Oropharynx 119 (31.1) 98 (60.5) 21 (9.5)  
Hypopharynx 28 (7.3) 5 (3.1) 23 (10.4)  
Larynx 38 (9.9) 8 (4.9) 30 (13.6)  
Histologic differentiation    <0.001 
  Well differentiated 141 (36.8) 32 (19.8) 109 (49.3)  
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  Moderated differentiated 192 (50.1) 96 (59.3) 96 (43.4)  
  Poorly differentiated 50 (13.1) 34 (21.0) 16 (7.2)  
Lymphovascular invasion    <0.001 
Yes 73 (19.1) 45 (27.8) 28 (12.7)  
No 310 (80.9) 117 (72.2) 193 (87.3)  
Perineural invasion    0.090 
Yes 51 (13.3) 16 (9.9) 35 (15.8)  
No 332 (86.7) 146 (90.1) 186 (84.2)  
Resection margin   0.011 
Positive 89 (23.2) 48 (29.6) 41 (18.6)  
Negative 294 (76.8) 114 (70.4) 180 (81.4)  
T stage    0.002 
T1 169 (44.1) 56 (34.6) 113 (51.1)  
T2 145 (37.9) 78 (48.1) 67 (30.3)  
T3 29 (7.6) 14 (8.6) 15 (6.8)  
T4 40 (10.4) 14 (8.6) 26 (11.8)  
N stage    0.001 
N0 167 (43.6) 56 (34.6) 111 (50.2)  
N1 69 (18.0) 26 (16.0) 43 (19.5)  
N2 145 (37.9) 80 (49.4) 65 (29.4)  
N3 2 (0.5) 0 (0.0) 2 (0.9)  
AJCC stage    0.001 
  Stage I 107 (27.9) 30 (18.5) 77 (34.8)  
Stage II 43 (11.2) 21 (13.0) 22 (10.0)  
  Stage III  69 (18.0) 26 (16.0) 43 (19.5)  
Stage IVA 162 (42.3) 85 (52.5) 77 (34.8)  
Stage IVB 2 (0.5) 0 (0.0) 2 (0.9)  
Adjuvant treatment   <0.001 
CCRT 95 (24.8) 46 (28.4) 49 (22.2)  
Radiotherapy 147 (38.4) 81 (50.0) 66 (29.9)  
No  141 (36.8) 35 (21.6) 106 (48.0)  
FGFR1 FISH amplification     
Number  
(median, range) 
2.08 
(1.55-10.08) 
2.06 
(1.62-5.43) 
2.10 
(1.55-10.08) 
0.001 
FGFR1/CEP8 ratio 
(median, range) 
0.99 
(0.43-5.13) 
1.00 
(0.58-2-23) 
0.97 
(0.43-5.13) 
0.185 
Abbreviations: AJCC, American Joint Committee on Cancer; CCRT, Concurrent 
chemoradiation therapy ; FGFR1, Fibroblast Growth Factor Receptor1; FISH, Fluorescent in 
situ hybridization 
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3. Survival Outcomes According to FGFR1 Amplification and p16 status 
With a median follow-up time of 53.1 months, the 5-year DFS and OS 
rates for all patients were 150 (39.2%) and 167 (43.6%), respectively. 
The median DFS for each of the three FGFR1 groups were not reached 
(Figure 2A). In comparison of mean survival, patients with high FGFR1 
amplification showed shorter DFS than those with low and no 
amplification (60.8 vs 95.2 months in low amplification and 95.9 months 
in no amplification, P=0.955). Figure 2B showed OS in Kaplan-Meier 
method, the median OS for one of the three FGFR1 groups were not 
reached. Regarding the mean survival, patients with high FGFR1 
amplification showed shorter OS than those with low and no 
amplification (64.0 vs 85.9 months in low amplification and 85.8 months 
in no amplification, P=0.933).  
 
Figure 2. Survival analysis on the bases of FGFR1 amplification (high, 
low, and no amplification). (A) Disease free survival, and (B) overall 
survival were not showed significant difference. 
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Based on p16 status, patients with p16 positive tumors had significantly 
better DFS and OS than patients with p16 negative tumors (Figure 3). 
For DFS, the hazard ratio (HR) was 0.42 (95% CI, 0.26 to 0.70), 
reflecting a 58% reduction in recurrence for patients with p16 positive 
tumors (P=0.001). For OS, the HR was 0.52 (95% CI, 0.36 to 0.75), 
reflecting a 48% reduction in death rate for patients with p16 positive 
tumors (P<0.001).  
 
Figure 3. Survival analysis on the bases of p16 status. (A) Disease free 
survival, and (B) overall survival were significantly better in patients 
with p16 positive tumors. 
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In Cox proportional hazard model adjusted for smoking, primary sites 
(oropharynx, hypopharynx), lymphovascular invasion, perineural 
invasion, positive resection margin, positive nodal status, p16 positive 
status and postoperative CCRT, p16 positive status was significantly 
associated with a longer OS (HR 0.48; 95% CI, 0.30-0.76; P=0.002, 
Table 4). Lymphovascular invasion, positive resection margin and 
positive nodal status were significantly related to shorter OS in 
multivariate analysis. There was no significant difference in OS for sex, 
smoking status, and FGFR1 amplification in multivariate analysis.  
 
Table 4. Univariate and multivariate analysis of overall survival  
 Univariate analysis Multivariate analysis 
 HR 95%CI P HR 95%CI P 
Sex 0.77 0.51-1.17 0.222    
Smoking 1.36 0.94-1.95 0.099    
Oral cavity 1.10 0.78-1.55 0.591    
Oropharynx 0.68 0.46-1.00 0.052 0.62 0.37-1.03 0.066 
Hypopharynx 1.70 0.96-3.02 0.069    
Larynx 1.26 0.71-2.24 0.438    
Lymphovascular invasion 1.89 1.28-2.80 0.002 1.78 1.17-2.73 0.008 
Perineural invasion 1.70 1.07-2.68 0.024    
Positive resection margin 1.57 1.08-2.29 0.019 1.62 1.09-2.41 0.018 
Positive nodal status 2.19 1.50-3.19 0.001 2.34 1.56-3.51 0.001 
p16 positive 0.52 0.36-0.75 0.001 0.48 0.30-0.76 0.002 
FGFR1 amplification  1.00 0.88-1.24 0.625    
CCRT  1.59 1.08-2.35 0.020    
Radiotherapy  0.87 0.61-1.23 0.425    
Abbreviations: HR, hazard  ration; 95% CI, 95% confidence intervals; FGFR1, 
Fibroblast Growth Factor Receptor1; CCRT, Concurrent chemoradiation therapy ; 
 
 
IV. DISCUSSION 
In this study, we investigated the frequency and the impact of FGFR1 
18 
amplification and p16 protein expression on clinical outcomes in patients with 
resected HNSCC. To our knowledge, this is the first report on the prognostic 
impact of FGFR1 amplification in the largest cohort of resected HNSCC patients 
from East Asians. Our study demonstrated the frequency of FGFR1 amplification 
is common 42.3% (1.0% for high amplification and 41.3% for low amplification) 
and there was no relation to prognostic impact on clinical outcomes. Regarding 
p16 status, a surrogate marker of oncogenic HPV infection, there were 42.4% of 
p16 positive tumors and related to favorable prognosis significantly. 
The frequency of FGFR1 amplification has been reported in squamous cell 
carcinoma of lung, esophagus, SCLC, and HNSCC, for which smoking is known 
dominant risk factor
10,12,13,30
. Overall, the frequency of FGFR1 amplification was 
reported to be 5.6-24.8% in lung SqCC
12
, and 6-9.4% in esophageal squamous 
cell carcinoma
13
. As determined by FISH analysis in our study, FGFR1 
amplification was 42.3%, which was higher compared to a value of 15% reported 
in a recent study in white patients from Western countries
14
. Of them, low 
FGFR1 amplification was observed more commonly in our study, 41.3% vs 
14.0%, respectively. There could be ethnic differences in the frequency of 
FGFR1 amplification and the prevalence of HPV infection. The other types of 
carcinoma reported variable ethnic difference in prevalence of FGFR1 
amplification. In SCLC, the frequency of FGFR1 amplification was reported to 
be 5.6-6% in western population
31
 and 1.9% in East Asian population
30
. In 
comparison, in esophageal squamous cell carcinoma, there are similar frequency 
between Western Europe and East Asia, 9.4% and 8.6%, respectively
13
.  
FGFR1 amplification has been known to be associated with poor prognosis or 
unfavorable clinicopathologic parameters in squamous cell carcinoma of lung, 
esophagus, and head and neck with several controversial results. In resected lung 
SqCC, Kim et al
12
 reported FGFR1 amplification as negative prognostic factor, 
whereas Heist et al
32
 observed no significant difference in OS. In HNSCC, 
FGFR1 amplification was significantly associated with poor prognostic factors 
such as higher T stage, lymphovascular invasion, and higher numbers of visceral 
metastases
14
. In our study, the prognostic impact of FGFR1 amplification was 
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not founded. Tumor heterogeneity in HNSCC, unstandardized FISH criteria for 
FGFR1 amplification, excellent surgical skills, varying adjuvant treatment, wide 
variation for FGFR1 amplification, and different frequency of FGFR1 alteration 
according to HPV status may contribute to the controversial results. In TCGA 
data
6
, FGFR1 alteration was higher (10%) in HPV negative group, and in HPV 
positive group, FGFR3 alteration was more common (11%).  
Unfortunately, standard definition for FGFR1 amplification by FISH is not 
established yet. Indeed, the definition of FGFR1 amplification by FISH 
technique has been highly variable in the previous studies
9,10,12,14,32,33
. Unlike 
breast cancer, lung SqCC exhibits small-clusters and co-amplifications of FGFR1 
and CEN8
33
. Therefore, FGFR1 FISH assay needs to differentiate between true 
amplification and polysomy in lung SqCC. In a large cohort study, Schildhause et 
al
33
 proposed a more sophisticated FGFR1 FISH criteria using average gene copy 
number per nucleus, FGFR1/CEN8 ratio, and percentage of gene clusters at the 
same time. By the addition of FGFR1/CEN8 ratio, 8 out of 47 cases (17.0%) 
were newly classified as high amplification in that study. In our study, we applied 
the FGFR1 FISH criteria in HNSCC previously proposed by Goke et al
14
, which 
not consider co-amplification of CEP8. Applied in our study, if the criteria for 
FGFR1/CEN8 ratio included, 14 patients (3.5%) might have been classified from 
low amplification group to high amplification group additionally. 
In the previous studies
10,12,13
, FGFR1 amplification may be an oncogenic driver 
mutation in tobacco-associated cancers of the aerodigestive tract. In our study, 
there was no relation between smoking status and survival outcomes. It’s caused 
by small sample size of high amplification and depending on medical record, 
underestimated amount of smoking by patients’ statement when they had visited 
to clinic in first time of diagnosis. 
In clinicopathologic characteristics of p16 negative group, several factors were 
known to be related good prognosis: favorable histologic differentiation, no 
lymphovascular invasion, negative resection margin, early pathologic stage. 
Nevertheless, p16 negative group had poor disease free and overall survival 
outcomes. As known in previous studies
26,34,35
, p16 protein expression was 
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confirmed as a strong and independent predictor of survival in oropharyngeal and 
nonoropharyngeal HNSCC. In p16 negative group, percentage of high/low 
FGFR1 amplification, and gene copy number of FGFR1 amplification were 
higher than in p16 positive group, suspiciously in which FGFR1 amplification 
had tendency for poor prognosis.  
Our study had several limitations. The main limitation includes its retrospective 
nature and selection bias for patient’s cohort. This is likely related to selection of 
surgically resected, earlier stage patients who relatively have favorable prognosis. 
And during process of manufacturing TMA, we excluded about 170 tissues for 
hypopharynx and larynx which had been decalcified. Because the sample 
included only a few high FGFR1 amplified tumors, we did not have enough 
statistical power to identify significant differences between the clinical 
characteristics of patients with FGFR1 amplification and those without FGFR1 
amplification. To identify such characteristics, a dedicate criteria with HNSCC 
will be needed.  
Several potent selective FGFR tyrosine kinase inhibitors are already in early 
clinical development. Tyrosine kinase inhibitors targeting multiple receptors 
including FGFR1 have been tried in lung SqCC. There are recent reports of 
promising results with the non-ATP competitive pan-FGFR selective inhibitor 
LY2874455
36
, the FGFR1-3 selective inhibitor AZD4547
37
, and the FGFR1-3 
selective inhibitor BGJ398
15
. Those agents are reported to have manageable 
toxicities including hyperphosphatemia, hypercalcemia, and ectopic tissue 
calcification; correlated with abnormal phosphate and vitamin D homeostasis 
caused by the blockage of FGF23 signaling
38
. Further clinical trials could show 
that FGFR1 inhibition has a therapeutic effect in FGFR1 amplified HNSCC. 
These emerging treatment strategies may shed light on treatment for patients with 
HNSCC who lack a specific therapeutic target. Further investigation for finding 
profit biomarkers and promising candidate drugs in clinical trials are currently 
ongoing and needed to proceed.  
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V. CONCLUSION 
In conclusion, we did not demonstrate the prognostic impact of FGFR1 
amplification in resected HNSCC. As known, p16 protein expression was 
confirmed as a strong and independent predictor of survival. Further research 
for finding a dedicate criteria for FGFR1 amplification and promising 
candidate drugs in clinical trials will be needed. 
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ABSTRACT (IN KOREAN) 
 
수술로 절제된 두경부 편평세포암에서  
FGFR1 유전자 증폭과 p16 단백질 발현의  
빈도 및 임상적 영향에 관한 연구 
 
<지도교수 조 병 철> 
 
연세대학교 대학원 의학과 
 
허 수 진 
 
 
본 연구의 목적은 수술로 절제된 두경부 편평세포암에서 
Fibroblast growth factor receptor 1 (FGFR1) 유전자 증폭과 p16 
단백질 발현의 빈도 및 임상적 영향에 대해 알아보고자 함이다. 
2005년 11월부터 2012년 12월까지 383명의 환자로부터 얻은 
조직으로 형광동소보합법의 기법을 사용하여 FGFR1 유전자 
증폭을 분석하였다. 이전 연구를 참고하여, 고증폭의 기준은 9개 
이상의 신호를 가진 종양세포가 20% 이상일 경우, 저증폭의 
기준은 2개 이상, 9개 미만의 신호를 가진 종양세포가 20% 
이상일 경우로 정하였다. 그 결과 FGFR1 고증폭은 1.0%, FGFR1 
저증폭은 41.3% 였고 FGFR1 증폭의 정도는 생존율과 관련성을 
보이지 않았고 p16 유전자 발현 양성은 42.4% 의 빈도로 
생존율 향상과 관련을 보였다. 두경부 종양의 부위별 이질성, 
형광동소보합법 기준의 비표준화, 수술 후 치료의 다양성, 넓은 
범위의 저증폭 환자비율 등이 이전 연구들의 결과와 차이점을 
보이는 것으로 생각된다. 추후 FGFR1 증폭 분석 기준의 
표준화에 대한 연구와 FGFR1 의 치료적 효용성에 대한 
추가적인 연구가 필요하겠다. 
---------------------------------------------------------------------------------------- 
핵심되는 말 : FGFR1, p16, 두경부 편평세포암  
